Back To: Home

CLICK HERE FOR WHAT'S NEW IN:
 




 

Codexis demonstrates proof of concept for PKU therapy
January 2015
by  |  Email the author
EDIT CONNECT

SHARING OPTIONS:

REDWOOD CITY, Calif.—Codexis Inc. has developed a novel enzyme therapeutic product candidate for the potential treatment of phenylketonuria (PKU) via oral administration. In PKU, the enzyme that converts phenylalanine into tyrosine is deficient, causing phenylalanine to accumulate in high levels in the brain, which leads to severe neurological problems such as intellectual disability, seizures and cognitive and behavioral problems. Studies conducted in an animal model of PKU demonstrated proof of concept for the product candidate, which, when introduced into the stomach of animal models, resulted in decreased blood phenylalanine levels. Codexis has filed patent applications covering the composition of matter for its enzymes and their use in treating PKU, and is seeking partners to advance the development of the PKU program. Preclinical studies for the enzyme therapeutic candidate are expected to begin next year.
 
Code:

Back



PAGE UTILITIES


CONTACT US
DDNEWS
Published by Old River Publications LLC
19035 Old Detroit Road
Rocky River, OH USA 44116
Ph: 440-331-6600  |  Fax: 440-331-7563
 
© Copyright 2019 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.